These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28764902)

  • 1. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.
    Ko WKD; Bezard E
    Exp Neurol; 2017 Dec; 298(Pt B):172-179. PubMed ID: 28764902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.
    Visanji NP; Brotchie JM; Kalia LV; Koprich JB; Tandon A; Watts JC; Lang AE
    Trends Neurosci; 2016 Nov; 39(11):750-762. PubMed ID: 27776749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
    Eschbach J; Danzer KM
    Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and α-synuclein expression.
    Devine MJ; Gwinn K; Singleton A; Hardy J
    Mov Disord; 2011 Oct; 26(12):2160-8. PubMed ID: 21887711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism.
    Osterberg VR; Spinelli KJ; Weston LJ; Luk KC; Woltjer RL; Unni VK
    Cell Rep; 2015 Mar; 10(8):1252-60. PubMed ID: 25732816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies.
    Hardenberg MC; Sinnige T; Casford S; Dada ST; Poudel C; Robinson EA; Fuxreiter M; Kaminksi CF; Kaminski Schierle GS; Nollen EAA; Dobson CM; Vendruscolo M
    J Mol Cell Biol; 2021 Aug; 13(4):282-294. PubMed ID: 33386842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease.
    Matsui H; Ito S; Matsui H; Ito J; Gabdulkhaev R; Hirose M; Yamanaka T; Koyama A; Kato T; Tanaka M; Uemura N; Matsui N; Hirokawa S; Yoshihama M; Shimozawa A; Kubo SI; Iwasaki K; Hasegawa M; Takahashi R; Hirai K; Kakita A; Onodera O
    Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2214652120. PubMed ID: 37252975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
    Oueslati A; Fournier M; Lashuel HA
    Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.